Dupixent in Type 2 COPD
COPD with Type 2 Inflammation
SponsorSanofi
1,800Enrollment Target
280Trial Sites
6Countries
March 2026Est. Completion
About This Trial
IL-4/IL-13 blockade for COPD patients with eosinophilic phenotype.
Primary Endpoints
- Annualized rate of moderate/severe exacerbations
- FEV1 change
Latest Update
February 2026
Primary endpoint met with 30% reduction in exacerbations. First biologic therapy for COPD potentially launching 2026.